share_log

榮昌生物：海外監管公告 - 第二屆董事會第十二次會議決議公告

REMEGEN: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 00:10
Summary by Moomoo AI
榮昌生物製藥（煙台）股份有限公司（「榮昌生物」）於2024年3月29日召開第二屆董事會第十二次會議，會議決議通過向特定對象發行人民幣普通股（A股）的方案。本次發行的股票種類為境內上市人民幣普通股，面值為1.00元，發行對象不超過35名特定投資者。發行股票的數量上限為70,763,170股，募集資金總額不超過255,000.00萬元，扣除相關發行費用後的淨額將用於新藥研發項目。發行完成後，股票將在上海證券交易所科創板上市交易，並且發行對象認購的A股股票將有6個月的限售期。本次發行的所有決議均獲得出席董事100%的同意票通過，並將提交公司股東大會逐項審議。
榮昌生物製藥（煙台）股份有限公司（「榮昌生物」）於2024年3月29日召開第二屆董事會第十二次會議，會議決議通過向特定對象發行人民幣普通股（A股）的方案。本次發行的股票種類為境內上市人民幣普通股，面值為1.00元，發行對象不超過35名特定投資者。發行股票的數量上限為70,763,170股，募集資金總額不超過255,000.00萬元，扣除相關發行費用後的淨額將用於新藥研發項目。發行完成後，股票將在上海證券交易所科創板上市交易，並且發行對象認購的A股股票將有6個月的限售期。本次發行的所有決議均獲得出席董事100%的同意票通過，並將提交公司股東大會逐項審議。
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) held the 12th meeting of the Second Board of Directors on March 29, 2024, and resolved to approve a plan to issue RMB Ordinary Shares (A Shares) to certain entities. The shares of this issue are domestic RMB ordinary shares with a face value of $1.00 and are issued to no more than 35 specific investors. The maximum number of shares to be issued is 70,763,170 shares, and the total amount raised will not exceed $255,000.00 million. The net amount after the related issuance costs will be used for new drug development projects. After the issue is completed, the shares will be listed on the Shanghai Stock Exchange's Technoboard, and the A-shares subscribed for by the issuer will have a 6-month selling period. All resolutions issued in this release are approved by 100% of the present directors and will be submitted to the Company's Annual General Meeting for consideration.
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. (“Wing Cheong Biologics”) held the 12th meeting of the Second Board of Directors on March 29, 2024, and resolved to approve a plan to issue RMB Ordinary Shares (A Shares) to certain entities. The shares of this issue are domestic RMB ordinary shares with a face value of $1.00 and are issued to no more than 35 specific investors. The maximum number of shares to be issued is 70,763,170 shares, and the total amount raised will not exceed $255,000.00 million. The net amount after the related issuance costs will be used for new drug development projects. After the issue is completed, the shares will be listed on the Shanghai Stock Exchange's Technoboard, and the A-shares subscribed for by the issuer will have a 6-month selling period. All resolutions issued in this release are approved by 100% of the present directors and will be submitted to the Company's Annual General Meeting for consideration.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more